Profound Medical Appoints Interim CFO; Former CFO Resigns

What Happened

• Profound Medical Corp. announced on August 14, 2026 that long-time finance executive Matthew Sobczyk has been appointed Interim Chief Financial Officer, effective the same date. Sobczyk has served in senior finance roles at the company since May 2017 and was Corporate Controller from March 2023 to August 2026.
• The company’s prior CFO, Rashed Dewan, resigned effective August 14, 2026. Profound entered a Mutual Separation Agreement with Dewan and a Contractor Services Agreement for transitional advisory services.

Key Details

• Interim CFO compensation: annual base salary of CAD 300,414.58 and eligibility for a discretionary bonus with a 15% target.
• Separation payment to former CFO: $375,000 cash severance plus employer-paid benefit contributions for 15 months; reimbursement up to CAD 5,000 for legal fees.
• Transition services: Dewan will provide contractor services from August 17, 2026 through November 25, 2026 at CAD 200 per hour and will continue vesting of 20,000 restricted share units.
• Vested stock options held by Dewan remain exercisable until the earlier of 12 months after the separation date or the options’ expiry.

Why It Matters

• Leadership: A change in the company’s finance leader is material for investors because the CFO role affects financial reporting, controls, and investor communications. The interim CFO is an internal promotion, which may support continuity.
• Costs and timing: The separation and contractor agreements create near-term cash costs (the $375,000 severance, benefit payments, and contractor fees) and equity-related timing (continued vesting and extended exercise windows) that investors may want to note.
• Disclosure: The company issued a press release under Regulation FD and disclosed that full agreements will be filed as exhibits with its next 10-Q, allowing investors to review the complete terms.